Trump Ibogaine Order: PTSD Veterans Research Boost
President Trump’s April 18 executive order fast-tracks ibogaine studies for PTSD and TBI in veterans, unlocking funding amid promising Stanford results showing 88% symptom cuts.
No reviews yet. Be the first to rate Nolan!
Nolan Williams, M.D., served as Professor of Psychiatry and Behavioral Sciences at Stanford University and Director of the Stanford Brain Stimulation Lab. He joined the Stanford faculty in 2014 as an instructor after completing residencies in psychiatry and neurology at the Medical University of South Carolina, where he earned his M.D. in 2008 following a bachelor’s degree in biology from the College of Charleston. Williams was promoted to assistant professor in 2019, associate professor in 2023, and full professor in 2025. He was double board-certified in neurology and psychiatry and maintained additional appointments by courtesy in Radiology.
Williams specialized in experimental therapeutic approaches for neuropsychiatric illnesses, with a focus on neuromodulation techniques including transcranial magnetic stimulation. He developed Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT or SNT), an accelerated, fMRI-guided form of TMS for treatment-resistant depression that received FDA clearance in 2022. His research also encompassed ibogaine therapy for PTSD, ketamine mechanisms, and brain stimulation applications for conditions such as bipolar disorder, OCD, and addiction. Williams led the Stanford Brain Stimulation Lab, overseeing numerous clinical trials and collaborations, and contributed to advancements in interventional psychiatry through publications on rapid-acting treatments and brain circuit modulation.
Professional Email: null
President Trump’s April 18 executive order fast-tracks ibogaine studies for PTSD and TBI in veterans, unlocking funding amid promising Stanford results showing 88% symptom cuts.